DR. ELSHAMI M ELAMIN MD NPI 1841254521

NPI Details

DR. Elshami M Elamin, MD is a medical oncology internal medicine in Newton, KS with 39 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Elshami M Elamin, MD NPI is 1841254521. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

730 MEDICAL CENTER DR
NEWTON, KS
ZIP 67114-778
Phone: (316) 283-1141
Fax: (316) 283-1162

The NPI 1841254521 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, tbo-filgrastim, 1 microgram (HCPCS:J1447)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, ferric derisomaltose, 10 mg (HCPCS:J1437)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, rituximab-abbs, biosimilar, (truxima), 10 mg (HCPCS:Q5115)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Injection, alteplase recombinant, 1 mg (HCPCS:J2997)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Telehealth originating site facility fee (HCPCS:Q3014)
• Declotting of central venous tube (HCPCS:36593)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)

The enumeration date for this NPI number is 4/12/2006 and was last updated on 10/10/2024.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: